Image

Melanoma Research

Featured image for “Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma”
06/15/2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

June 14, 2021 08:03 AM Eastern Daylight Time  | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Alkermes’s disappointment hones melanoma niche focus”
06/04/2021

Alkermes’s disappointment hones melanoma niche focus

June 04, 2021  | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma”
04/15/2021

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

  Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Lifileucel Proves Efficacy in Pretreated Advanced Melanoma”
04/14/2021

Lifileucel Proves Efficacy in Pretreated Advanced Melanoma

  Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
03/11/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  March 11, 2021 | Source: PRNewswire   DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma”
02/05/2021

Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma

  March 11, 2021|  Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
01/26/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  January 24, 2021 19:07 ET | Source: Junshi Biosciences   Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Why Is the Tissue Bank So Important For Melanoma Research?”
01/08/2021

Why Is the Tissue Bank So Important For Melanoma Research?

  We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment;…
Blog - Melanoma360
Melanoma Research
Featured image for “What is Oral Parity, and Why Does it Matter?”
01/08/2021

What is Oral Parity, and Why Does it Matter?

  We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain…
Blog - Melanoma360
Melanoma Research
06/15/2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

June 14, 2021 08:03 AM Eastern Daylight Time  | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
Featured image for “Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/04/2021

Alkermes’s disappointment hones melanoma niche focus

June 04, 2021  | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Featured image for “Alkermes’s disappointment hones melanoma niche focus”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/15/2021

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

  Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
Featured image for “Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/14/2021

Lifileucel Proves Efficacy in Pretreated Advanced Melanoma

  Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
Featured image for “Lifileucel Proves Efficacy in Pretreated Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
03/11/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  March 11, 2021 | Source: PRNewswire   DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/05/2021

Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma

  March 11, 2021|  Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
Featured image for “Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/26/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  January 24, 2021 19:07 ET | Source: Junshi Biosciences   Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/08/2021

Why Is the Tissue Bank So Important For Melanoma Research?

  We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment;…
Featured image for “Why Is the Tissue Bank So Important For Melanoma Research?”
Blog - Melanoma360
 | 
Melanoma Research
01/08/2021

What is Oral Parity, and Why Does it Matter?

  We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain…
Featured image for “What is Oral Parity, and Why Does it Matter?”
Blog - Melanoma360
 | 
Melanoma Research